|
||||||||||||||||||
|
||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionThe TRA-1-81 antibody recognizes a protein expressed on undifferentiated human embryonic stem cells (ES), embyronal carcinoma cells (EC), and embryonic germ cells (EG). Like other stem cell specific markers, the epitope recognized by the TRA-1-81 antibody is lost upon cell differentiation. The TRA-1-81 epitope is resistant to neuraminidase digestion, unlike the epitope recognized by the related TRA-1-60 antibody. The TRA-1-81 antibody is known to specifically recognize a carbohydrate epitope on a keratan sulfated glycoprotein recently identified as podocalyxin, a member of the CD34-related family of sialomucins. Podocalyxin is a transmembrane glycoprotein originally identified on epithelial glomerular cells known as podocytes, and the protein has also been implicated in the development of aggressiveness in a variety of cancers, including breast and prostate cancer. Applications ReportedFor research use only, not for diagnostic or therapeutic use. This TRA-1-81 antibody has been reported for use in flow cytometric analysis. Applications TestedThis TRA-1-81 antibody has been tested by flow cytometric analysis of the human embryonal carcinoma (EC) line 2102Ep. This can be used at less than or equal to 0.25 μg per million cells in a 100 μl total staining volume. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. References
Schopperle WM, DeWolf WC. The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells. 2007 Mar;25(3):723-30. (TRA-1-81, WB, PubMed) Xu C, Inokuma MS, Denham J, Golds K, Kundu P, Gold JD, Carpenter MK. Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol. 2001 Oct;19(10):971-4. (PubMed) Badcock G, Pigott C, Goepel J, Andrews PW. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Cancer Res. 1999 Sep 15;59(18):4715-9. (TRA-1-81, WB, PubMed) Andrews PW, Banting G, Damjanov I, Arnaud D, Avner P. Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. Hybridoma. 1984 Winter;3(4):347-61. (PubMed) Related ProductsCat. 11-4317 Streptavidin-FITC (Fluorescein isothiocyanate) Cat. 12-4317 Streptavidin-PE (Phycoerythrin) Cat. 17-4317 Streptavidin Allophycocyanin (SA-APC) Cat. 14-8813 Affinity Purified anti-mouse/human SSEA-1 (stage-specific embryonic antigen-1) (clone eBioMC-480 (MC-480)) Cat. 14-8833 Affinity Purified anti-human/mouse SSEA-3 (stage-specific embryonic antigen-3) (clone eBioMC-631 (MC-631)) Cat. 14-8843 Affinity Purified anti-human SSEA-4 (stage-specific embryonic antigen-4) (clone eBioMC-813-70 (MC-813-70)) Cat. 12-8863 Phycoerythrin (PE) anti-human TRA-1-60 (podocalyxin) (clone TRA-1-60) Cat. 13-8863 Biotin anti-human TRA-1-60 (podocalyxin) (clone TRA-1-60) Cat. 14-8863 Affinity Purified anti-human TRA-1-60 (podocalyxin) (clone TRA-1-60) |
|||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |